To determine the levels, cellular origin and procoagulant function of microparticles in ET and PV, and to explore the existence of a correlation with jak2V617F mutation, medication and vascular events.
ID
Source
Brief title
Condition
- Haematopoietic neoplasms (excl leukaemias and lymphomas)
- Embolism and thrombosis
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Number of Annexin V positive microparticles in patients and controls as well as
the expression of different antibodies in this Annexin V positive.
Endogene trombine potential of patients and controls.
We will describe the relationship of these microparticles with medication,
jak2V17 mutation and history of thrombo-embolic events in patients and controls
Secondary outcome
We will describe the relation between these microparticles and Von Willebrand
factor antigen and propeptide, E-selectin, thrombocytes, age and gender.
Background summary
Thromboembolic complications are common in patients with Essential
Thrombocythaemia (ET) and Polycythemia Vera (PV). Their pathogenesis is not
completely explained, neither by platelet count, nor by platelet function
although abnormalities have been described. We hypothesize a role for cellular
microparticles (MPs), since they are known to be elevated in thromboembolic
diseases, like myocardial infarction and venous thromboembolism.
Study objective
To determine the levels, cellular origin and procoagulant function of
microparticles in ET and PV, and to explore the existence of a correlation with
jak2V617F mutation, medication and vascular events.
Study design
We will analyse samples of 20 patients meeting the WHO criteria for ET, and 30
patients meeting the WHO criteria for PV, and we will analyse 30 controls. We
will use previously described methods for flowcytometry to determine number and
origin of cellular microparticles.
Study burden and risks
No extra risk or burden for patients.
Oosterpark 9
1090 HM Amsterdam
Nederland
Oosterpark 9
1090 HM Amsterdam
Nederland
Listed location countries
Age
Inclusion criteria
patients who meet WHO criteria for PV and ET
Exclusion criteria
we have no exclusion criteria
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL18428.067.07 |